Q2 - Novozymes

More documents

Recommendations

Info

About GroPep Ltd.• Based in Adelaide, Australia with local listing (GRO)• Develops, manufactures and commercialises biologically activeproteins for cell culture and biomedical research• Main activity is within cell culture ingredients and the sale ofLONG TM R 3 IGF-1• Biopharmaceutical drug development programme• 80 employees and approximately 20%of revenues are spent on R&D• Robust margins38Unlocking the magic of nature
GroPep financial figuresGroPep key financial figures:AUDm(Year end 30 Jun)03/04 4 04/05 4 1H05 5 1H06 5Total revenues 13.1 16.7 7.8 8.4Pre tax profit 1.0 3.1 1.3 2.1Net profit 1.0 6.5 0.8 1.5GroPep segmented results 2004/2005 4 :AUDm(Year end 30 Jun)BiologicalproductsConsolidatedTotal revenues 14.2 16.7Pre tax profit 6.3 3.1Source: GroPep accounts4) In accordance with previous GAAP (Australian GAAP)5) In accordance with AIFRS (AUS equivalent to IFRS)39Unlocking the magic of nature
Page 2 and 3: Key messages in 1H 2006• Healthy
Page 4 and 5: Detergent enzymes - business update
Page 6: Food enzymes - business update• S
Page 10 and 11: R&D news• Confident outlook for t
Page 13 and 14: Currency risk management• Favoura
Page 15 and 16: Business development update• Over
Page 17 and 18: GroPep acquisition proposalNovozyme
Page 19 and 20: Forward-looking statementsThis pres
Page 21 and 22: Novozymes - brief introduction• D
Page 23 and 24: Enzymes and microorganisms are used
Page 25 and 26: New products, applications and mark
Page 27 and 28: Current business composition- new p
Page 29 and 30: Novozymes strategy•New productsEn
Page 31 and 32: All long-term financial targets met
Page 33 and 34: Balance sheetDKK millionFixed asset
Page 35 and 36: How we produce enzymes? (I/II)Micro
Page 37: GroPep proposal - Strategy & ration
Page 41 and 42: Recognised as a leader in sustainab
Page 43: Biotech-based world leaderin enzyme

Q2 - Novozymes

Create successful ePaper yourself

Delete template?

Save as template?